Person:
GARİP, GÜNSELİ AYŞE

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

GARİP

First Name

GÜNSELİ AYŞE

Name

Filters

20191
Reset filters

Settings

End date: 2019 × Has files: true ×

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    PublicationOpen Access
    Synergistic Effects of 4-Aminopyridine and Paclitaxel on MCF 7 Cell Line
    (MARMARA UNIV, INST HEALTH SCIENCES, 2019-09-15) GARİP, GÜNSELİ AYŞE; Aydogmus, Esra M. Cuce; Garip, Gunseli Ayse Inhan
    Objectives: Aim of this study is to increase the effectiveness of paclitaxel (PTX) with the use of 4 - aminopyridine (4-AP) on breast cancer cell line MCF-7. Methods: In this study, L-929 (ATCC CRL-6364) and MCF-7 (ATCC - HTB 22) cell lines were used. IC50 and survival values were determined by trypan blue exclusion; cell cycle analysis was determined by measuring levels of Cdk2 and Histone (H3) and plasma membrane potential (Vm) measurements were performed using fluorescent Bis-(1,3-dibutylbarbituric acid) trimethine oxonol (DiBaC4(3)). Results: IC50 values were determined for two agents and these values were combined. Combination treatments ie. 4-AP (4 mM) + PTX (5 nM) and 4-AP (4 mM) + PTX (7.5 nM) decreased viability 17% +/- 8.08 and 45% +/- 3.18, respectively for L-929 cells and decreased viability 60%+/- 3.7 and 74%+/- 2.6, respectively for MCF-7 cells. For L-929 cells, plasma membrane potential measurements resulted in depolarization for 4-AP, PTX (5 nM) and PTX (7.5 nM), and resulted in hyperpolarization for the combinations. For MCF-7 cells, plasma membrane potential measurements resulted in depolarization for 4-AP, PTX (7.5 nM) and 4-AP + PTX (5 nM), and resulted in hyperpolarization for PTX (5 nM) and 4-AP + PTX (7.5 nM). Changes of Cdk2 and H3 levels showed mostly G1 arrest for MCF-7 cells and G2/M arrest for L-929 cells. Conclusions: Combination treatments increased the cell death for MCF-7 cells. But, combination treatments didn't show synergistic effect on L-929 which is accepted as a non-cancerous cell. These data showed that use of 4-AP in combination with the anticancer agent paclitaxel is a promising approach for cancer treatment.